PharmiWeb.com - Global Pharma News & Resources
19-Dec-2018

Global Transplant Complications Drug Development Pipeline Review 2018 Featuring Medeor Therapeutics, Amgen and Novartis

Global Transplant Complications Drug Development Pipeline Review 2018 Featuring Medeor Therapeutics, Amgen and Novartis

PR Newswire

DUBLIN, Dec. 18, 2018

DUBLIN, Dec. 18, 2018 /PRNewswire/ --

The "Transplant Complications Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

This report Transplant Complications Drug Development Pipeline Review, 2018, provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products.

GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment consists of immunosuppressants. There are 125 products in development for GVHD.

Organ transplantation replaces an injured or diseased organ with a healthy one. Following a transplant, the immune system may consider the transplanted tissue as foreign and work against it. Patients can develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously.

These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, blocking organ rejection and facilitating a successful transplant. There are 18 products in development for liver transplant rejection, 49 products in development for kidney transplant rejection and 12 products in development for lung transplant rejection.

Molecular targets acted on by products in development for transplantation complications include tyrosine kinases, caspases and chemokine receptors. Companies operating in this pipeline space include Medeor Therapeutics, Amgen and Novartis.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each.
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these.
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Key Topics Covered:

1 Introduction
1.1 Transplant Complications Report Coverage
1.2 Graft Versus Host Disease (GVHD) - Overview
1.3 Liver Transplant Rejection - Overview
1.4 Kidney Transplant Rejection - Overview
1.5 Lung Transplant Rejection - Overview

2 Therapeutics Development
2.1 Graft Versus Host Disease (GVHD)
2.2 Liver Transplant Rejection
2.3 Kidney Transplant Rejection
2.4 Lung Transplant Rejection

3 Therapeutics Assessment
3.1 Graft Versus Host Disease (GVHD)
3.2 Liver Transplant Rejection
3.3 Kidney Transplant Rejection
3.4 Lung Transplant Rejection

4 Companies Involved in Therapeutics Development
4.1 Graft Versus Host Disease (GVHD)
4.2 Liver Transplant Rejection
4.3 Kidney Transplant Rejection
4.4 Lung Transplant Rejection

5 Dormant Projects
5.1 Graft Versus Host Disease (GVHD)
5.2 Liver Transplant Rejection
5.3 Kidney Transplant Rejection
5.4 Lung Transplant Rejection

6 Discontinued Products
6.1 Graft Versus Host Disease (GVHD)
6.2 Liver Transplant Rejection
6.3 Kidney Transplant Rejection

7 Product Development Milestones
7.1 Graft Versus Host Disease (GVHD)
7.2 Liver Transplant Rejection
7.3 Kidney Transplant Rejection
7.4 Lung Transplant Rejection

8 Appendix

Companies Mentioned

  • AbbVie Inc
  • AbGenomics International Inc
  • Alexion Pharmaceuticals Inc
  • AnaptysBio Inc
  • Angion Biomedica Corp
  • apceth Biopharma GmbH
  • Aptevo Therapeutics Inc
  • Astellas Pharma Inc
  • Athersys Inc
  • Balmes Transplantation SAS
  • Bellicum Pharmaceuticals Inc
  • Biogen Inc
  • Bioverativ Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Catalyst Biosciences Inc
  • Cell2B Advanced Therapeutics SA
  • Cellect Biotechnology Ltd
  • Cellective BioTherapy Inc
  • Cynata Therapeutics Ltd
  • Cytodyn Inc
  • Dompe Farmaceutici SpA
  • Elsalys Biotech SA
  • enGene Inc
  • Enlivex Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Generon (Shanghai) Corp Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Hansa Medical AB
  • Idogen AB
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • ITB-Med AB
  • Jazz Pharmaceuticals Plc
  • Kadmon Corp LLC
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kidney Transplant Rejection
  • Kymab Ltd
  • Kyowa Hakko Kirin Co Ltd
  • LG Chem Ltd
  • Liver Transplant Rejection
  • MaaT Pharma
  • Magenta Therapeutics Inc
  • MallInckrodt Plc
  • Medicenna Therapeutics Corp
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • Noorik Biopharmaceuticals AG
  • OncoImmune Inc
  • Opsona Therapeutics Ltd
  • Pfizer Inc
  • Pharming Group NV
  • Pluristem Therapeutics Inc
  • Prolong Pharmaceuticals LLC
  • Quark Pharmaceuticals Inc
  • RedHill Biopharma Ltd
  • REGiMMUNE Corp
  • Sanofi
  • Seattle Genetics Inc
  • Seres Therapeutics Inc
  • Shire Plc
  • Sublimity Therapeutics Ltd
  • Syndax Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TC BioPharm Ltd
  • TolerogenixX GmbH
  • United BioPharma Inc
  • Vault Pharma Inc
  • VBI Vaccines Inc
  • Veloxis Pharmaceuticals A/S
  • Visterra Inc
  • Xenikos BV
  • XL-protein GmbH
  • Zai Lab Ltd

For more information about this report visit https://www.researchandmarkets.com/research/vzj6fp/global_transplant?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-transplant-complications-drug-development-pipeline-review-2018-featuring-medeor-therapeutics-amgen-and-novartis-300768317.html

SOURCE Research and Markets

Editor Details

Last Updated: 19-Dec-2018